Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNYBiotechnology
-$6.27 today
- Market cap
- $20.01B
- Beta
- 0.27
- P/E (TTM)
- 63.6
- EPS (TTM)
- $4.34
Volume 2.52M
Average 1.11M
ALNY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $413.13M rose 27.7% year over year, behind the +30.1% change in trailing-twelve-month research & development. Sequentially, it rose 13.2% from the prior quarter. Over 3 fiscal years it compounded at +14.5% a year.
Context
- Research & development amounted to 35.7% of revenue in FY2025, down 14.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +27.7% toward the trailing-twelve-month pace of +30.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 1.32B USD
- Year-over-year change
- +17.6%
- 4-year CAGR
- +13.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.32B | +17.6% |
| FY2024 | 2024-12-31 | 1.13B | +12.1% |
| FY2023 | 2023-12-31 | 1B | +13.7% |
| FY2022 | 2022-12-31 | 883.02M | +11.5% |
| FY2021 | 2021-12-31 | 792.16M | — |
Research & Development vs competitors
How ALNY compares with its peers on the latest reported figures
- ALNY's LTM Jun 2026 research & development of $1.51B is the highest of the 6 companies compared; the peer median is $361.17M.
- Its year-over-year change of +30.1% is the highest of 5, against a peer median of +9.2%.
- Research & development amounts to 31.4% of revenue for ALNY, versus a peer median of 264.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.51B | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Sep 2026 | $739.14M | +21.7% | +29.3% | 164.0% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Mar 2026 | $189.6M | +13.6% | +16.4% | 264.1% | |
| LTM Mar 2026 | $61.84M | — | +24.0% | 6710.8% | |
| Peer median (excluding ALNY) | $361.17M | +9.2% | +16.4% | 264.1% | |
Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 844.29M | 1.04B | 1.83B | 2.25B | 3.71B |
| Cost of Revenue | 140.14M | 168.82M | 310.41M | 323.37M | 677.17M |
| Gross Profit | 704.14M | 868.6M | 1.52B | 1.92B | 3.04B |
| Gross Margin | 83.4% | 83.7% | 83.0% | 85.6% | 81.8% |
| Research & Development | 792.16M | 883.02M | 1B | 1.13B | 1.32B |
| Selling, General & Admin | 620.64M | 770.66M | 795.65M | 975.53M | 1.21B |
| Operating Expenses | 1.41B | 1.65B | 1.8B | 2.1B | 2.54B |
| Depreciation & Amortization | 47.57M | 44.47M | 54.05M | 56.67M | 55.66M |
| EBITDA | (661.56M) | (926.56M) | (258.24M) | (178.85M) | 631.44M |
| EBITDA Margin | -78.4% | -89.3% | -14.1% | -8.0% | 17.0% |
| Operating Income | (708.65M) | (785.07M) | (282.18M) | (176.89M) | 501.58M |
| Operating Margin | -83.9% | -75.7% | -15.4% | -7.9% | 13.5% |
| Interest Income | 1.58M | 24.81M | 95.56M | 121.99M | 111.47M |
| Interest Expense | 143.02M | 155.97M | 121.22M | 141.86M | 252.63M |
| Other Income / Expenses | (143.49M) | (341.92M) | (151.34M) | (200.49M) | (178.43M) |
| Income Before Tax | (852.14M) | (1.13B) | (433.52M) | (377.38M) | 323.15M |
| Pre-Tax Margin | -100.9% | -108.6% | -23.7% | -16.8% | 8.7% |
| Income Tax Expense | 680K | 4.16M | 6.73M | (99.22M) | 9.41M |
| Net Income | (852.82M) | (1.13B) | (440.24M) | (278.16M) | 313.75M |
| Net Margin | -101.0% | -109.0% | -24.1% | -12.4% | 8.4% |
| EPS (Basic) | (7.20) | (9.30) | (3.52) | (2.18) | 2.39 |
| EPS (Diluted) | (7.20) | (9.30) | (3.52) | (2.18) | 2.33 |
| Weighted Avg Shares | 118.45M | 121.69M | 124.91M | 127.65M | 131M |
| Weighted Avg Shares (Diluted) | 118.45M | 121.69M | 124.91M | 127.65M | 134.68M |
Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY
Intrinsic Alpha fair value
Locked
Current Price
$149.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.